CRIS Current Research Information System

CASADEI, BEATRICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.337
EU - Europa 2.487
AS - Asia 1.472
AF - Africa 154
SA - Sud America 12
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.468
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.324
IT - Italia 710
CN - Cina 501
SE - Svezia 473
SG - Singapore 436
GB - Regno Unito 432
DE - Germania 328
VN - Vietnam 281
IN - India 148
IE - Irlanda 111
FR - Francia 82
RU - Federazione Russa 79
TG - Togo 54
FI - Finlandia 53
CI - Costa d'Avorio 38
ZA - Sudafrica 37
JO - Giordania 34
UA - Ucraina 34
EE - Estonia 30
ID - Indonesia 27
NL - Olanda 26
CH - Svizzera 24
NG - Nigeria 24
BG - Bulgaria 23
BE - Belgio 18
AT - Austria 14
CA - Canada 12
ES - Italia 10
PL - Polonia 10
HK - Hong Kong 8
IR - Iran 7
BR - Brasile 6
JP - Giappone 6
PK - Pakistan 6
CZ - Repubblica Ceca 5
LB - Libano 5
RO - Romania 5
AU - Australia 4
DK - Danimarca 4
HR - Croazia 3
IL - Israele 3
MK - Macedonia 3
MY - Malesia 3
AR - Argentina 2
CL - Cile 2
LT - Lituania 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
TR - Turchia 2
BD - Bangladesh 1
BY - Bielorussia 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
UZ - Uzbekistan 1
Totale 7.468
Salva come PNG Salva come JPEG
Città #
Singapore 397
Fairfield 387
Southend 373
Chandler 330
Santa Clara 272
Ashburn 250
Houston 183
Woodbridge 173
Dong Ket 166
Bologna 165
Seattle 158
Wilmington 151
Princeton 136
Ann Arbor 134
Boardman 120
Cambridge 117
Dublin 111
Berlin 66
Milan 59
Lomé 54
Beijing 48
Helsinki 45
Redmond 43
Nanjing 39
Rome 39
Abidjan 38
Hyderabad 38
New York 38
Westminster 38
Bremen 36
Jinan 35
Amman 34
San Diego 30
Turin 29
Padova 27
Jakarta 26
Abeokuta 23
Guangzhou 22
Bern 21
Changsha 19
Shenyang 19
Tianjin 19
Brussels 18
Florence 17
Sofia 17
Dearborn 16
Los Angeles 15
Des Moines 14
Hebei 14
Saint Petersburg 14
Olalla 13
Amsterdam 12
Taizhou 12
Hangzhou 11
Jacksonville 11
Jiaxing 11
Modena 11
Nanchang 11
Shanghai 11
Catania 10
London 10
Vienna 10
Hong Kong 8
Lappeenranta 8
Paris 8
Shenzhen 8
Toronto 8
Wuhan 8
Zhengzhou 8
Calderara di Reno 7
Norwalk 7
Nuremberg 7
Parma 7
Reggio Emilia 7
Verona 7
Warsaw 7
Adelfia 6
Bühl 6
Casalecchio di Reno 6
Chengdu 6
Chicago 6
Frankfurt am Main 6
Ravenna 6
Redwood City 6
Dongguan 5
Medford 5
Moscow 5
Mülheim 5
Phoenix 5
Tokyo 5
Vicenza 5
Cinisello Balsamo 4
Forlì 4
Foshan 4
Fuzhou 4
Haikou 4
Imola 4
Monmouth Junction 4
Murmansk 4
Naples 4
Totale 4.990
Salva come PNG Salva come JPEG
Nome #
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 236
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 222
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 182
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 164
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 153
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 153
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 151
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 150
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 145
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 144
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 136
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 134
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 132
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 125
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 124
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 124
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 123
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 123
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 120
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 118
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 118
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 117
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 116
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 116
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 115
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 114
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 110
Vemurafenib mucosal side-effect. 107
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 107
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 106
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma 105
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 104
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 101
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 101
New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia 99
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: Bridge to transplant 97
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 91
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 90
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 89
Impressive continuous complete response after mogamulizumab in a heavily pretreated Sézary syndrome patient 89
Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides) 87
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 87
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 85
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 85
Erythrodermie mit Brentuximab‐Vedotin (Hautnebenwirkungen bei Mycosis fungoides) 83
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 81
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 78
null 75
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 73
Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report 70
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy 69
Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report 68
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 66
Spontaneous remission of follicular lymphoma 66
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 64
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 64
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 62
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas 61
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 59
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 58
Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity 58
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 54
Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient 47
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 45
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors 45
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 44
Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report 44
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 41
Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review 40
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 40
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 39
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 39
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 37
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases 37
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 35
Follicular lymphoma: the diminishing role of chemotherapy. 33
Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report 33
Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation 33
Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers 32
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma 31
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma 30
Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. 28
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 26
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy 26
Endobronchial Presentation of Hodgkin Lymphoma Responding to Pembrolizumab: A Case Report 24
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 24
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 24
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 24
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection 23
Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report 22
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi 22
Gut Microbiota Role in Response to Checkpoint Inhibitor Treatment in Patients with Relapsed/Refractory B-Cell Hodgkin Lymphoma: The MICRO-Linf Study 21
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 20
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 20
Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) 20
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study 19
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 18
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study 16
Mogamulizumab-associated rashes, their presentation and prognostic significance: a single-centre retrospective case series analysis 16
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 11
Totale 7.733
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.493
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.493
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020935 0 0 0 0 0 150 169 185 197 102 55 77
2020/2021794 107 46 25 15 14 16 22 39 106 44 43 317
2021/20221.226 121 56 59 106 97 62 23 93 44 118 270 177
2022/20231.678 142 223 117 202 124 125 55 138 260 53 129 110
2023/2024739 56 98 67 88 64 90 37 54 24 66 39 56
2024/20251.645 169 322 299 233 432 190 0 0 0 0 0 0
Totale 7.739